Juvenile Idiopathic Arthritis Clinical Trials

27 recruiting

Juvenile Idiopathic Arthritis Trials at a Glance

42 actively recruiting trials for juvenile idiopathic arthritis are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Not Applicable with 10 trials, with the heaviest enrollment activity in Hamburg, Valencia, and Hamilton. Lead sponsors running juvenile idiopathic arthritis studies include Istanbul University - Cerrahpasa, Eli Lilly and Company, and Alfasigma S.p.A..

Browse juvenile idiopathic arthritis trials by phase

Treatments under study

About Juvenile Idiopathic Arthritis Clinical Trials

Looking for clinical trials for Juvenile Idiopathic Arthritis? There are currently 27 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Juvenile Idiopathic Arthritis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Juvenile Idiopathic Arthritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting
Phase 2

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Juvenile Idiopathic Arthritis
Sanofi51 enrolled31 locationsNCT02991469
Recruiting
Phase 3

OLE Study With Filgotinib in JIA

Juvenile Idiopathic Arthritis (JIA)
Alfasigma S.p.A.80 enrolled4 locationsNCT07553182
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Phase 3

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Duke University400 enrolled6 locationsNCT06654882
Recruiting

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

FibromyalgiaSystemic Lupus ErythematosusJuvenile Idiopathic Arthritis
Children's National Research Institute90 enrolled1 locationNCT04833465
Recruiting
Phase 2

Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis
R-Pharm International, LLC71 enrolled14 locationsNCT07517575
Recruiting

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

Psoriatic Arthritis, JuvenilePolyarticular Juvenile Idiopathic Arthritis
Pfizer10 enrolled1 locationNCT05754710
Recruiting

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Hidradenitis SuppurativaJuvenile Idiopathic ArthritisPediatric Plaque Psoriasis
Novartis Pharmaceuticals76 enrolled1 locationNCT07243782
Recruiting
Phase 3

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis
Eli Lilly and Company190 enrolled82 locationsNCT03773965
Recruiting
Phase 3

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company58 enrolled55 locationsNCT04088396
Recruiting
Phase 3

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Juvenile Idiopathic Arthritis
AbbVie90 enrolled44 locationsNCT05609630
Recruiting

Ilaris NIS in Korea

Systemic Juvenile Idiopathic Arthritis (sJIA)Hereditary Periodic Fever SyndromesCryopyrin-associated Periodic Syndromes (CAPS)+3 more
Novartis Pharmaceuticals25 enrolled1 locationNCT06838143
Recruiting
Not Applicable

Feasibility of a Diet Intervention for Juvenile Arthritis

Juvenile Idiopathic ArthritisArthritis, JuvenileArthritis, Childhood
The Hospital for Sick Children54 enrolled7 locationsNCT06474546
Recruiting
Phase 2

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Juvenile Rheumatoid Arthritis (JRA)Primary Immunodeficiency (PID)Congenital Bone Marrow Failure Syndromes+4 more
Paul Szabolcs100 enrolled1 locationNCT01962415
Recruiting
Phase 1

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Juvenile Idiopathic Arthritis
Alfasigma S.p.A.10 enrolled10 locationsNCT06222034
Recruiting

Dynamic Gait Index as a Functional Gait Assessment Measure in Children With JIA

Juvenile Idiopathic ArthritisChildhood Rheumatic Disease
Istanbul University - Cerrahpasa52 enrolled1 locationNCT06870045
Recruiting
Not Applicable

Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis (JIA)
Istanbul University - Cerrahpasa30 enrolled1 locationNCT07234747
Recruiting
Not Applicable

Pain in Juvenile Arthritis

Juvenile Idiopathic Arthritis
Washington University School of Medicine140 enrolled1 locationNCT07217782
Recruiting

Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients

Juvenile Idiopathic Arthritis (JIA)Childhood Rheumatic Diseases
Hacettepe University50 enrolled1 locationNCT07185750
Recruiting
Phase 1

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Systemic Sclerosis (SSc)Polyarticular Juvenile Idiopathic ArthritisPrimary Sjogren's Syndrome+1 more
Chongqing Precision Biotech Co., Ltd11 enrolled1 locationNCT07184450